The Strategist

Unilever buys a number of GlaxoSmithKline assets in Asia for € 3.3 billion


12/04/2018 - 09:45



International consumer goods manufacturer Unilever has signed an agreement with one of the world's largest pharmaceutical companies, the British GlaxoSmithKline (GSK). Unilever is going to buy GSK’s assets for the production of healthy food products and beverages in Bangladesh, India and other Asian countries, according to the press release.



Judgefloro
Judgefloro
The company explains that the deal consists of three elements. First, the merger of two company divisions in India, Hindustan Unilever Ltd (HUL) with GSK Consumer Healthcare India (GSK CH India), will be realized. Secondly, Unilever will buy an 82% stake in GSK in Bangladesh - GSK Bangladesh Limited, and third, the company will have a number of assets in 20 countries outside India.

Unilever points out that the turnover of GSK's business in the field of food and beverage health food production in 2018 was approximately 550 million euro, primarily due to the Horlicks and Boost brands. At the same time, approximately 90% of the turnover falls on India.

The cost of the entire transaction is 4.6 billion euro, of which Unilever will pay 3.3 billion euro in cash and new shares of its Indian unit HUL. The transaction is expected to be completed approximately 12 months after receiving approval of shareholders and regulatory authorities.

“This deal meets Unilever’s stated strategy to increase its presence in healthy food categories and in fast-growing emerging markets,” the press release said.

At the same time, GlaxoSmithKline (GSK) announced acquisition of Tesaro, an American pharmaceutical company specializing in oncological diseases, for $ 5.1 billion, according to the press release release.

“GlaxoSmithKline plc and Tesaro Inc today announced that the companies have entered into a final agreement under which GSK will acquire Tesaro, a company specializing in oncology... for a total of about 5.1 billion dollars (4 billion pounds),” the company said.

It is noted that the purchase will help GSK significantly strengthen its portfolio by replenishing it with Zejula, a drug for treatment of ovarian cancer, as well as a number of other cancer drugs that Tesaro now produces.

The transaction is expected to be closed in the first quarter of 2019.

Pharmaceutical GlaxoSmithKline was founded in 2001 in the UK through the merger of GlaxoWellcome and SmithKline Beecham. Headquartered in Brentford.

Unilever was founded in 1930 as a result of the merger of the Dutch Margarine Uni and the British Lever Brothers. Currently, the company has approximately 400 brands in its portfolio in 170 countries. Among them are Lux, Sunsilk, Timotei, Denim, Dove, Rexona, Domestos, Knorr, Lipton, Brooke Bond. About 163 thousand employees work at 264 Unilever production facilities in one hundred countries of the world.

source: bloomberg.com




More
< >

Monday, December 10th 2018 - 11:54 ALM Intelligence names leaders in consulting services